psilocybin
Commercial- Indications
- Depression, PTSD, Anxiety, Alcohol addiction, Anorexia nervosa, Obsessive-compulsive disorder, Tourette syndrome
Company intelligence / Profile preview
Natural MedTech is developing biosynthetic and proprietary formulations of psychedelic compounds such as psilocybin and DMT. The company partners with leading Australian universities to develop sustainable manufacturing processes. Their products are being used in formal clinical research targeting major depressive disorder and other mental health conditions. A referenced Phase 2 study using psilocybin showed a remission rate of 79% in patients with major depressive disorder after two doses. The company is active in both preclinical development and supplying GMP-grade materials for ongoing clinical studies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Natural MedTech.